HALO
Halozyme Therapeutics, Inc. · Healthcare · Biotechnology
动量输入（同类管理人）：
持有人广度 +4.8% ·
股份流向 +7.6% ·
净新建仓位 0.0%
· 公式
广泛增持：持股数量上升，持有人数量增加
所有持股数据：仅限已追踪的 13F 管理人，普通股持仓，报告期 Q3 2025
| 季度 | 持有人 | Δ | 股份 | 报告持仓市值 | 新增 | 清仓 |
|---|---|---|---|---|---|---|
| Q3 2026 | 3 | 0 | 502.79K | $49.11M | n/a | −1 |
| Q2 2026 | 131 | -1 | 91.15M | $6.60B | +6 | −8 |
| Q1 2026 | 136 | +1 | 88.77M | $5.36B | +7 | −7 |
| Q4 2025 | 135 | -1 | 97.38M | $6.16B | +1 | −1 |
| Q3 2025 | 22 | +1 | 49.86M | $3.66B | +1 | −1 |
| Q2 2025 | 19 | 0 | 43.24M | $2.25B | n/a | n/a |
| Q1 2025 | 16 | -1 | 15.61M | $996.39M | n/a | −1 |
| Q4 2024 | 17 | +3 | 17.59M | $840.95M | +4 | −1 |
| Q3 2024 | 13 | -1 | 6.97M | $398.81M | n/a | −1 |
| Q2 2024 | 14 | n/a | 8.14M | $426.06M | n/a | n/a |
| # | 管理人 | 股份 | Δ股份 | 价值 | 其权重 | 持有 | ||
|---|---|---|---|---|---|---|---|---|
| 1 | The Vanguard Group ✦ (被动) | 11.63M | -5.0% | $852.93M | 0.0% | ▼ Trim | 2 | SEC ↗ ×5 |
| 2 | State Street Global Advisors ✦ (被动) | 5.02M | -15.4% | $368.11M | 0.0% | ▼ Trim | 4 | SEC ↗ ×2 |
| 3 | Arrowstreet Capital ✦ | 3.29M | +29.5% | $241.34M | 0.2% | ▲ Add | 6 | SEC ↗ |
| 4 | D. E. Shaw & Co. ✦ | 2.65M | +160.2% | $194.38M | 0.2% | ▲ Add | 6 | SEC ↗ ×2 |
| 5 | Geode Capital Management ✦ (被动) | 2.43M | -0.1% | $178.34M | 0.0% | ▼ Trim | 6 | SEC ↗ ×2 |
| 6 | Morgan Stanley ✦ | 1.74M | n/a | $127.44M | 0.0% | n/c | 1 | SEC ↗ ×18 |
| 7 | JPMorgan Chase ✦ | 1.54M | n/a | $112.63M | 0.0% | n/c | 1 | SEC ↗ ×22 |
| 8 | Two Sigma Investments ✦ | 1.32M | +199.2% | $96.51M | 0.2% | ▲ Add | 6 | SEC ↗ |
| 9 | Millennium Management ✦ | 1.23M | +77.8% | $90.03M | 0.1% | ▲ Add | 6 | SEC ↗ ×2 |
| 10 | Renaissance Technologies ✦ | 1.00M | +195.4% | $73.36M | 0.1% | ▲ Add | 6 | SEC ↗ |
| 11 | AQR Capital Management ✦ | 968.51K | +155.7% | $71.03M | 0.0% | ▲ Add | 6 | SEC ↗ ×5 |
| 12 | Capital World Investors ✦ | 831.66K | +6.3% | $60.99M | 0.0% | ▲ Add | 4 | SEC ↗ ×2 |
| 13 | T. Rowe Price ✦ | 825.42K | -20.0% | $60.54M | 0.0% | ▼ Trim | 6 | SEC ↗ ×2 |
| 14 | Goldman Sachs Group ✦ | 684.52K | n/a | $50.20M | 0.0% | n/c | 1 | SEC ↗ ×5 |
| 15 | Bridgewater Associates ✦ | 487.08K | 新增 | $35.72M | 0.1% | New | 1 | SEC ↗ |
| 16 | Fisher Asset Management ✦ | 410.89K | +7.6% | $30.13M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 17 | Marshall Wace ✦ | 393.75K | +1.2% | $28.88M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 18 | Gotham Asset Management ✦ | 252.93K | +271.7% | $18.55M | 0.1% | ▲ Add | 6 | SEC ↗ |
| 19 | Citadel Advisors ✦ | 244.80K | -21.4% | $17.95M | 0.0% | ▼ Trim | 4 | SEC ↗ ×3 |
| 20 | Wellington Management ✦ | 37.13K | -64.2% | $2.72M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 21 | Fidelity (FMR) ✦ | 20.75K | -75.5% | $1.52M | 0.0% | ▼ Trim | 2 | SEC ↗ ×6 |
"持仓权重"指该仓位占该管理人13F申报股票组合市值的比例，即持仓信心指标。✦ = 精选管理人。
新增买入方
| Bridgewater Associates | $35.72M | 0.1% |
已清仓
| Norges Bank | $45.03M | 曾为 0.0% |
全市场背景: 涵盖所有13F申报机构（SEC结构化数据， Q1 2026): 630 持有人, 119.44M 股份, $7.40B 已申报. 这是与上方被追踪全域数据不同的较早期间，两者从不混用。
持有该证券的受追踪机构最常同时持有的其他证券：基于共同持有计数，而非基本面关联。
公开市场买入 (P)
在我们的覆盖窗口内无内部人士公开市场买入记录。
公开市场卖出 (S)
Officer, Director · 200 股 · $22,102
Officer, Director · 11.90K 股 · $1.31M
Officer, Director · 3.09K 股 · $336,526
Officer, Director · 4.81K 股 · $520,341
Officer, Director · 8.60K 股 · $954,867
Officer, Director · 200 股 · $22,739
Officer, Director · 900 股 · $101,502
Officer, Director · 10.30K 股 · $1.15M
Officer, Director · 1.78K 股 · $197,245
Officer, Director · 9.92K 股 · $1.09M
授予、行权及税务代扣代缴在本平台均不计入买入或卖出。 方法论